BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120:3787-851. [PMID: 32202104 DOI: 10.1021/acs.chemrev.9b00738] [Cited by in Crossref: 140] [Cited by in F6Publishing: 152] [Article Influence: 70.0] [Reference Citation Analysis]
Number Citing Articles
1 Mulero F, Oteo M, Garaulet G, Magro N, Rebollo L, Medrano G, Santiveri C, Romero E, Sellek RE, Margolles Y, Campos-olivas R, Arroyo AG, Fernández LA, Morcillo MA, Martínez-torrecuadrada JL. Development of anti-membrane type 1-matrix metalloproteinase nanobodies as immunoPET probes for triple negative breast cancer imaging. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1058455] [Reference Citation Analysis]
2 Suman SK, Mukherjee A, Pandey U, Chakraborty A, Rakshit S, Tawate M, Sarma HD. 68Ga-Labeled Trastuzumab Fragments for ImmunoPET Imaging of Human Epidermal Growth Factor Receptor 2 Expression in Solid Cancers. Cancer Biotherapy and Radiopharmaceuticals 2022. [DOI: 10.1089/cbr.2022.0042] [Reference Citation Analysis]
3 Lugat A, Bailly C, Chérel M, Rousseau C, Kraeber-Bodéré F, Bodet-Milin C, Bourgeois M. Immuno-PET: Design options and clinical proof-of-concept. Front Med (Lausanne) 2022;9:1026083. [PMID: 36314010 DOI: 10.3389/fmed.2022.1026083] [Reference Citation Analysis]
4 Kang CS, Zhang S, Wang H, Liu Y, Ren S, Chen Y, Li J, Bandara N, Rogachev AY, Rogers BE, Chong H. Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability. ACS Omega. [DOI: 10.1021/acsomega.2c03478] [Reference Citation Analysis]
5 Wei W, Jiang D, Evangelista L, Cai W. Antibody-Based Imaging and Therapy for Precision Medicine. Mol Pharm 2022;19:3453-5. [PMID: 36184938 DOI: 10.1021/acs.molpharmaceut.2c00606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Khadria A, Paavola CD, Maslov K, Brown-augsburger PL, Grealish PF, Lozano E, Blankenship RL, Cao R, Shi J, Beals JM, Oladipupo SS, Wang LV. Photoacoustic imaging reveals transient decrease of oxygenation in murine blood due to monoclonal IgG4 antibody.. [DOI: 10.1101/2022.09.29.509334] [Reference Citation Analysis]
7 Yuan F, Sun H, Yang C, Yang H, Pan L, Zhang X, Tian R, Li L, Chen W, Wu X, Wu H. Difluorocarbene-derived rapid late-stage trifluoromethylation of 5-iodotriazoles for the synthesis of 18F-labeled radiotracers. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.107960] [Reference Citation Analysis]
8 Syed M, Cagely M, Dogra P, Hollmer L, Butner JD, Cristini V, Koay EJ. Immune‐checkpoint inhibitor therapy response evaluation using oncophysics‐based mathematical models. WIREs Nanomed Nanobiotechnol 2022. [DOI: 10.1002/wnan.1855] [Reference Citation Analysis]
9 Zhao H, Qin Y, Liu D, Geng X, Wang C, Ding D, Ding X, Xia Q, Liu J, Wang R, Tan W. Site-Specific Radioiodination of Oligonucleotides with a Phenolic Element in a Programmable Approach. Molecules 2022;27:6257. [DOI: 10.3390/molecules27196257] [Reference Citation Analysis]
10 Sun J, Huangfu Z, Yang J, Wang G, Hu K, Gao M, Zhong Z. Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation. Adv Drug Deliv Rev 2022;:114538. [PMID: 36162696 DOI: 10.1016/j.addr.2022.114538] [Reference Citation Analysis]
11 Lindsley CW, Müller CE, Bongarzone S. Diagnostic and Therapeutic Radiopharmaceuticals. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.2c00173] [Reference Citation Analysis]
12 Lindsley CW, Müller CE, Bongarzone S. Diagnostic and Therapeutic Radiopharmaceuticals. J Med Chem . [DOI: 10.1021/acs.jmedchem.2c01403] [Reference Citation Analysis]
13 Imura R, Kumakura Y, Yan L, Shimoura Y, Takahashi H, Ida H, Wada Y, Akimitsu N. DOTA chelation through click chemistry enables favorable biodistribution of 89Zr-radiolabeled antibodies: A comparison with DFO chelation.. [DOI: 10.1101/2022.09.08.507067] [Reference Citation Analysis]
14 Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, Zhou D, Wang R, Gong J, Miao Q, Kang L, Yang J. Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging 2022. [PMID: 36063202 DOI: 10.1007/s00259-022-05954-y] [Reference Citation Analysis]
15 Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. BJR 2022;95. [DOI: 10.1259/bjr.20220379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhu H, Geng T, Tang K. The cyclotriphosphazene-based covalent organic frameworks constructed entirely by flexible building blocks for adsorping and fluorescence sensing iodine. Microporous and Mesoporous Materials 2022;343:112165. [DOI: 10.1016/j.micromeso.2022.112165] [Reference Citation Analysis]
17 Mulero Aniorte F. ImmunoPET in oncology. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2022;41:332-339. [DOI: 10.1016/j.remnie.2022.08.001] [Reference Citation Analysis]
18 Mulero Aniorte F. InmunoPET en oncología. Revista Española de Medicina Nuclear e Imagen Molecular 2022;41:332-339. [DOI: 10.1016/j.remn.2022.08.001] [Reference Citation Analysis]
19 Yan G, Wang X, Fan Y, Lin J, Yan J, Wang L, Pan D, Xu Y, Yang M. Immuno-PET Imaging of TNF-α in Colitis Using 89Zr-DFO-infliximab. Mol Pharm 2022. [PMID: 36039398 DOI: 10.1021/acs.molpharmaceut.2c00411] [Reference Citation Analysis]
20 Filippi L, Evangelista L, Sathekge MM, Schillaci O. ImmunoPET for prostate cancer in the PSMA era: do we need other targets? Clin Transl Imaging. [DOI: 10.1007/s40336-022-00520-w] [Reference Citation Analysis]
21 Liu D, Xia Q, Ding D, Tan W. Radiolabeling of functional oligonucleotides for molecular imaging. Front Bioeng Biotechnol 2022;10:986412. [DOI: 10.3389/fbioe.2022.986412] [Reference Citation Analysis]
22 Bhise A, Park H, Lee W, Sarkar S, Ha YS, Rajkumar S, Nam B, Lim JE, Huynh PT, Lee K, Son JY, Kim JY, Lee KC, Yoo J. Preclinical Evaluation of hnRNPA2B1 Antibody in Human Triple-Negative Breast Cancer MDA-MB-231 Cells via PET Imaging. Pharmaceutics 2022;14:1677. [PMID: 36015303 DOI: 10.3390/pharmaceutics14081677] [Reference Citation Analysis]
23 Li D, Li X, Zhao J, Tan F. Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. J Transl Med 2022;20:358. [PMID: 35962347 DOI: 10.1186/s12967-022-03559-5] [Reference Citation Analysis]
24 Xiong Y, Zhang Y, Li Z, Reza MS, Li X, Tian X, Ai HW. Engineered Amber-Emitting Nano Luciferase and Its Use for Immunobioluminescence Imaging In Vivo. J Am Chem Soc 2022. [PMID: 35913786 DOI: 10.1021/jacs.2c02320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Triumbari EKA, Morland D, Laudicella R, Bauckneht M, Albano D, Annunziata S. Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review. Cancers 2022;14:3488. [DOI: 10.3390/cancers14143488] [Reference Citation Analysis]
26 Southcott L, Wharton L, Rousseau J, Merkens H, Yang H, Bénard F, Orvig C. Trastuzumab-conjugated oxine-based ligand for [89Zr]Zr4+ immunoPET. J Inorg Biochem 2022;235:111936. [PMID: 35878576 DOI: 10.1016/j.jinorgbio.2022.111936] [Reference Citation Analysis]
27 Jin GQ, Chau CV, Arambula JF, Gao S, Sessler JL, Zhang JL. Lanthanide porphyrinoids as molecular theranostics. Chem Soc Rev 2022;51:6177-209. [PMID: 35792133 DOI: 10.1039/d2cs00275b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
28 Kim JW, Ko JH, Sage J. DLL3 REGULATES NOTCH SIGNALING IN SCLC.. [DOI: 10.1101/2022.07.08.499386] [Reference Citation Analysis]
29 Qi T, McGrath K, Ranganathan R, Dotti G, Cao Y. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Adv Drug Deliv Rev 2022;188:114421. [PMID: 35809868 DOI: 10.1016/j.addr.2022.114421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Fernandes EFA, Wilbs J, Raavé R, Jacobsen CB, Toftelund H, Helleberg H, Boswinkel M, Heskamp S, Gustafsson MBF, Bjørnsdottir I. Comparison of the Tissue Distribution of a Long-Circulating Glucagon-like Peptide-1 Agonist Determined by Positron Emission Tomography and Quantitative Whole-Body Autoradiography. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.2c00075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Wang Q, Zhang X, Wei W, Cao M. PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. Mol Pharm 2022. [PMID: 35771950 DOI: 10.1021/acs.molpharmaceut.2c00353] [Reference Citation Analysis]
32 Manafi-farid R, Ataeinia B, Ranjbar S, Jamshidi Araghi Z, Moradi MM, Pirich C, Beheshti M. ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. Front Med 2022;9:916693. [DOI: 10.3389/fmed.2022.916693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jin GQ, Guo LJ, Zhang J, Gao S, Zhang JL. Luminescent Metal Complexes for Bioassays in the Near-Infrared (NIR) Region. Top Curr Chem (Cham) 2022;380:31. [PMID: 35715540 DOI: 10.1007/s41061-022-00386-6] [Reference Citation Analysis]
34 Wang S, Liu F, Wang P, Wen L, Wang Z, Guo Q, Zhu H, Yang Z. 124I Radiolabeled Basiliximab for CD25-Targeted Immuno-PET Imaging of Activated T Cells. Mol Pharm 2022. [PMID: 35704773 DOI: 10.1021/acs.molpharmaceut.2c00330] [Reference Citation Analysis]
35 Gupta A, Sood A, Fuhrer E, Djanashvili K, Agrawal G. Polysaccharide-Based Theranostic Systems for Combined Imaging and Cancer Therapy: Recent Advances and Challenges. ACS Biomater Sci Eng 2022;8:2281-306. [PMID: 35513349 DOI: 10.1021/acsbiomaterials.1c01631] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Matiz CA, Delaney S, Cook BE, Genady AR, Hoerres R, Kuchuk M, Makris G, Valliant JF, Sadeghi S, Lewis JS, Hennkens HM, Bryan JN, Zeglis BM. Pretargeted PET of Osteodestructive Lesions in Dogs. Mol Pharmaceutics. [DOI: 10.1021/acs.molpharmaceut.2c00220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Shao F, Pan Z, Long Y, Zhu Z, Wang K, Ji H, Zhu K, Song W, Song Y, Song X, Gai Y, Liu Q, Qin C, Jiang D, Zhu J, Lan X. Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. J Nanobiotechnology 2022;20:243. [PMID: 35614462 DOI: 10.1186/s12951-022-01444-3] [Reference Citation Analysis]
38 Xiong Y, Zhang Y, Li Z, Reza MS, Li X, Tian X, Ai H. An Engineered Amber-Emitting Nano Luciferase and Its Use for Immunobioluminescence Imaging in Vivo.. [DOI: 10.1101/2022.05.23.493143] [Reference Citation Analysis]
39 Hayashi T, Hinata N. Current status and future prospects of antibody-drug conjugates in urological malignancies. Int J Urol 2022. [PMID: 35581739 DOI: 10.1111/iju.14925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lian X, Scott-Thomas A, Lewis JG, Bhatia M, MacPherson SA, Zeng Y, Chambers ST. Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives. Int J Mol Sci 2022;23:5563. [PMID: 35628374 DOI: 10.3390/ijms23105563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Tisseraud M, Goutal S, Bonasera T, Goislard M, Desjardins D, Le Grand R, Parry CM, Tournier N, Kuhnast B, Caillé F. Isotopic Radiolabeling of the Antiretroviral Drug [18F]Dolutegravir for Pharmacokinetic PET Imaging. Pharmaceuticals 2022;15:587. [DOI: 10.3390/ph15050587] [Reference Citation Analysis]
42 Wu Q, Huang G, Wei W, Liu J. Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. Mol Pharm 2022. [PMID: 35510710 DOI: 10.1021/acs.molpharmaceut.2c00034] [Reference Citation Analysis]
43 Fite BZ, Wang J, Ghanouni P, Ferrara KW. A Review of Imaging Methods to Assess Ultrasound-Mediated Ablation. BME Frontiers 2022;2022:1-17. [DOI: 10.34133/2022/9758652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Biegon A, Cohen S, Franceschi D. Modulation of Secondary Cancer Risks from Radiation Exposure by Sex, Age and Gonadal Hormone Status: Progress, Opportunities and Challenges. JPM 2022;12:725. [DOI: 10.3390/jpm12050725] [Reference Citation Analysis]
45 Hussain M, Ali W, Amjed N, Wajid AM, Aslam MN. An overview of nuclear data standardisation work for accelerator-based production of medical radionuclides in Pakistan. Radiochimica Acta 2022;0. [DOI: 10.1515/ract-2022-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ghosh S, Huda P, Fletcher NL, Howard CB, Walsh B, Campbell D, Pinkham MB, Thurecht KJ. Antibody-Based Formats to Target Glioblastoma: Overcoming Barriers to Protein Drug Delivery. Mol Pharm 2022. [PMID: 35438509 DOI: 10.1021/acs.molpharmaceut.1c00996] [Reference Citation Analysis]
47 Fay R, Törő I, Schinke A, Simic B, Schaefer JV, Dreier B, Plückthun A, Holland JP. Sortase-Mediated Site-Specific Conjugation and 89 Zr-Radiolabeling of Designed Ankyrin Repeat Proteins for PET. Mol Pharmaceutics. [DOI: 10.1021/acs.molpharmaceut.2c00136] [Reference Citation Analysis]
48 Yang E, Liu Q, Huang G, Liu J, Wei W. Engineering nanobodies for next-generation molecular imaging. Drug Discov Today 2022:S1359-6446(22)00123-4. [PMID: 35331925 DOI: 10.1016/j.drudis.2022.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Floresta G, Abbate V. Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography. Med Res Rev 2022. [PMID: 35292998 DOI: 10.1002/med.21885] [Reference Citation Analysis]
50 Ji H, Yuan L, Jiang Y, Ye M, Liu Z, Xia X, Qin C, Jiang D, Gai Y, Lan X. Visualizing Cytokeratin-14 Levels in Basal-Like Breast Cancer via ImmunoSPECT Imaging. Mol Pharmaceutics. [DOI: 10.1021/acs.molpharmaceut.2c00004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, Fehrman E, Pardons M, Kumar S, Deitchman AN, Ravanfar V, Schulte B, Wu IK, Pan T, Reeves JD, Nixon CC, Iyer NS, Torres L, Munter SE, Hyunh T, Petropoulos CJ, Hoh R, Franc BL, Gama L, Koup RA, Mascola JR, Chomont N, Deeks SG, VanBrocklin HF, Henrich TJ. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun 2022;13:1219. [PMID: 35264559 DOI: 10.1038/s41467-022-28727-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Cheng Y, Shi D, Xu Z, Gao Z, Si Z, Zhao Y, Ye R, Fu Z, Fu W, Yang T, Xiu Y, Lin Q, Cheng D. 124I-Labeled Monoclonal Antibody and Fragment for the Noninvasive Evaluation of Tumor PD-L1 Expression In Vivo. Mol Pharm 2022. [PMID: 35244407 DOI: 10.1021/acs.molpharmaceut.2c00084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Niu M, Qin J, Wang L, He Y, Tian C, Chen Y, Huang P, Peng Z, Bogdanov A. Evaluation of [18F]tetrafluoroborate as a Potential PET Imaging Agent in a Sodium Iodide Symporter-Transfected Cell Line A549 and Endogenous NIS-Expressing Cell Lines MKN45 and K1. Molecular Imaging 2022;2022:1-13. [DOI: 10.1155/2022/2679260] [Reference Citation Analysis]
54 Ng TSC, Allen HH, Rashidian M, Miller MA. Probing immune infiltration dynamics in cancer by in vivo imaging. Curr Opin Chem Biol 2022;67:102117. [PMID: 35219177 DOI: 10.1016/j.cbpa.2022.102117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Shin J, Parker MFL, Zhu I, Alanizi A, Rodriguez CI, Liu R, Watchmaker PB, Kalita M, Blecha J, Luu J, Wright B, Lapi SE, Flavell RR, Okada H, Tlsty TD, Roybal KT, Wilson DM. Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.. [DOI: 10.1101/2022.02.16.480729] [Reference Citation Analysis]
56 Li L, Zhong L, Tang C, Gan L, Mo T, Na J, He J, Huang Y. CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target. Clin Transl Oncol 2022. [PMID: 35165838 DOI: 10.1007/s12094-022-02792-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Li D, Li X, Yang J, Shi Z, Zhang L, Li R, Peng Y, Liu J, Zuo C. Nivolumab-DTPA-Based PD-1 Imaging Reveals Structural and Pathological Changes in Colorectal Carcinoma. Front Bioeng Biotechnol 2022;10:839756. [DOI: 10.3389/fbioe.2022.839756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Hoang TT, Mandleywala K, Viray T, Tan KV, Lewis JS, Pereira PMR. EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors. Mol Imaging Biol 2022. [PMID: 35147837 DOI: 10.1007/s11307-022-01708-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, Huang G, Liu J. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging 2022. [PMID: 35147737 DOI: 10.1007/s00259-022-05723-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
60 Mukai H, Ogawa K, Kato N, Kawakami S. Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics. Drug Metabolism and Pharmacokinetics 2022. [DOI: 10.1016/j.dmpk.2022.100450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
61 Gosmann D, Russelli L, Weber WA, Schwaiger M, Krackhardt AM, D'Alessandria C. Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy. EJNMMI Res 2022;12:5. [PMID: 35099641 DOI: 10.1186/s13550-022-00877-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Etrych T, Braunova A, Zogala D, Lambert L, Renesova N, Klener P. Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas. Cancers (Basel) 2022;14:626. [PMID: 35158894 DOI: 10.3390/cancers14030626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
63 Madden PJ, Arif MS, Becker ME, McRaven MD, Carias AM, Lorenzo-Redondo R, Xiao S, Midkiff CC, Blair RV, Potter EL, Martin-Sancho L, Dodson A, Martinelli E, Todd JM, Villinger FJ, Chanda SK, Aye PP, Roy CJ, Roederer M, Lewis MG, Veazey RS, Hope TJ. Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques. Front Immunol 2021;12:810047. [PMID: 35003140 DOI: 10.3389/fimmu.2021.810047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Jiang D, Wu X, Sun X, Tan W, Dai X, Xie Y, Du A, Zhao Q. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11. J Nanobiotechnology 2022;20:29. [PMID: 35012554 DOI: 10.1186/s12951-021-01206-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
65 Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, Grayson PC, McAdoo SP, Mason JC, Owen C, Weyand CM, Youngstein T, Dhaun N. Large-vessel vasculitis. Nat Rev Dis Primers 2022;7:93. [PMID: 34992251 DOI: 10.1038/s41572-021-00327-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
66 Chen KT, Zaharchuk G. Image synthesis for low-count PET acquisitions: lower dose, shorter time. Biomedical Image Synthesis and Simulation 2022. [DOI: 10.1016/b978-0-12-824349-7.00025-6] [Reference Citation Analysis]
67 Thomas E, Mathieu C, Moreno-Gaona P, Mittelheisser V, Lux F, Tillement O, Pivot X, Ghoroghchian PP, Detappe A. Anti-BCMA Immuno-NanoPET Radiotracers for Improved Detection of Multiple Myeloma. Adv Healthc Mater 2022;11:e2101565. [PMID: 34710281 DOI: 10.1002/adhm.202101565] [Reference Citation Analysis]
68 Li H, Luo Q, Zhang H, Ma X, Gu Z, Gong Q, Luo K. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Chem Soc Rev 2022. [DOI: 10.1039/d2cs00437b] [Reference Citation Analysis]
69 Sun H, Xue Q, Zhang C, Wu H, Feng P. Derivatization based on tetrazine scaffolds: synthesis of tetrazine derivatives and their biomedical applications. Org Chem Front 2022;9:481-98. [DOI: 10.1039/d1qo01324f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
70 Alam IS, Shaffer TM, Gambhir SS. Nuclear Imaging of Endogenous Markers of Lymphocyte Response. Nuclear Medicine and Immunology 2022. [DOI: 10.1007/978-3-030-81261-4_2] [Reference Citation Analysis]
71 Rousseau J, Lau J, Bénard F. Radiolabeled Antibodies for Cancer Radioimmunotherapy. Nuclear Medicine and Immunology 2022. [DOI: 10.1007/978-3-030-81261-4_14] [Reference Citation Analysis]
72 Hermann P, Kotek J, Kubíček V. Ten-Membered Rings or Lager With One or More Nitrogen Atoms. Comprehensive Heterocyclic Chemistry IV 2022. [DOI: 10.1016/b978-0-12-818655-8.00128-1] [Reference Citation Analysis]
73 Ruiz-López E, Calatayud-Pérez J, Castells-Yus I, Gimeno-Peribáñez MJ, Mendoza-Calvo N, Morcillo MÁ, Schuhmacher AJ. Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography. Cancers (Basel) 2021;14:74. [PMID: 35008238 DOI: 10.3390/cancers14010074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
74 Hu Y, Miao Y, Zhang J, Chen Y, Qiu L, Lin J, Ye D. Alkaline Phosphatase Enabled Fluorogenic Reaction and in situ Coassembly of Near-Infrared and Radioactive Nanoparticles for in vivo Imaging. Nano Lett 2021;21:10377-85. [PMID: 34898218 DOI: 10.1021/acs.nanolett.1c03683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
75 Southcott L, Li L, Patrick BO, Stephan H, Jaraquemada-Peláez MG, Orvig C. [nat/89Zr][Zr(pypa)]: Thermodynamically Stable and Kinetically Inert Binary Nonadentate Complex for Radiopharmaceutical Applications. Inorg Chem 2021;60:18082-93. [PMID: 34788042 DOI: 10.1021/acs.inorgchem.1c02709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Wei W, Zhang D, Wang C, Zhang Y, An S, Chen Y, Huang G, Liu J. Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053. Mol Pharm 2021. [PMID: 34846151 DOI: 10.1021/acs.molpharmaceut.1c00733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Wei W, Zhang Y, Zhang D, Liu Q, An S, Chen Y, Huang G, Liu J. Annotating BCMA Expression in Multiple Myelomas. Mol Pharm 2021. [PMID: 34843261 DOI: 10.1021/acs.molpharmaceut.1c00628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Dun Y, Huang G, Liu J, Wei W. ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality. Drug Discov Today 2021:S1359-6446(21)00500-6. [PMID: 34838729 DOI: 10.1016/j.drudis.2021.11.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
79 Hansen SB, Bender D. Advancement in production of radiotracers. Semin Nucl Med 2021:S0001-2998(21)00079-9. [PMID: 34836618 DOI: 10.1053/j.semnuclmed.2021.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
80 Zhou X, Dong L, Shen L. Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals. Molecules 2021;26:6997. [PMID: 34834087 DOI: 10.3390/molecules26226997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Kang L, Li C, Yang Q, Sutherlin L, Wang L, Chen Z, Becker KV, Huo N, Qiu Y, Engle JW, Wang R, He C, Jiang D, Xu X, Cai W. 64Cu-labeled daratumumab F(ab')2 fragment enables early visualization of CD38-positive lymphoma. Eur J Nucl Med Mol Imaging 2021. [PMID: 34677626 DOI: 10.1007/s00259-021-05593-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
82 Al Tabaa Y, Bailly C, Kanoun S. FDG-PET/CT in Lymphoma: Where Do We Go Now? Cancers (Basel) 2021;13:5222. [PMID: 34680370 DOI: 10.3390/cancers13205222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
83 Hrynchak I, Santos L, Falcão A, Gomes CM, Abrunhosa AJ. Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies. IJMS 2021;22:10745. [DOI: 10.3390/ijms221910745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
84 Kiraga Ł, Kucharzewska P, Paisey S, Cheda Ł, Domańska A, Rogulski Z, Rygiel TP, Boffi A, Król M. Nuclear imaging for immune cell tracking in vivo – Comparison of various cell labeling methods and their application. Coordination Chemistry Reviews 2021;445:214008. [DOI: 10.1016/j.ccr.2021.214008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Russelli L, De Rose F, Leone L, Reder S, Schwaiger M, D'Alessandria C, Tei L. A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging. Molecules 2021;26:5819. [PMID: 34641362 DOI: 10.3390/molecules26195819] [Reference Citation Analysis]
86 Jiang D, Younis MH, Lan X, Cai W. High-performance renal imaging with a radiolabeled, non-excretable chimeric fusion protein. Theranostics 2021;11:9177-9. [PMID: 34522233 DOI: 10.7150/thno.66417] [Reference Citation Analysis]
87 Lan X, Fan K, Cai W. First-in-human study of an 18F-labeled boramino acid: a new class of PET tracers. Eur J Nucl Med Mol Imaging 2021;48:3037-40. [PMID: 33547555 DOI: 10.1007/s00259-021-05227-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Feiner IVJ, Brandt M, Cowell J, Demuth T, Vugts D, Gasser G, Mindt TL. The Race for Hydroxamate-Based Zirconium-89 Chelators. Cancers (Basel) 2021;13:4466. [PMID: 34503276 DOI: 10.3390/cancers13174466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
89 Alluri SR, Higashi Y, Kil KE. PET Imaging Radiotracers of Chemokine Receptors. Molecules 2021;26:5174. [PMID: 34500609 DOI: 10.3390/molecules26175174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Lv G, Miao Y, Chen Y, Lu C, Wang X, Xie M, Qiu L, Lin J. Promising potential of a 18F-labelled small-molecular radiotracer to evaluate PD-L1 expression in tumors by PET imaging. Bioorg Chem 2021;115:105294. [PMID: 34426150 DOI: 10.1016/j.bioorg.2021.105294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
91 Suzuki H, Kise S, Kaizuka Y, Watanabe R, Sugawa T, Furukawa T, Fujii H, Uehara T. Copper-64-Labeled Antibody Fragments for Immuno-PET/Radioimmunotherapy with Low Renal Radioactivity Levels and Amplified Tumor-Kidney Ratios. ACS Omega 2021;6:21556-62. [PMID: 34471758 DOI: 10.1021/acsomega.1c02516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
92 Lan X, Younis MH, Li K, Cai W. First clinical experience of 106 cm, long axial field-of-view (LAFOV) PET/CT: an elegant balance between standard axial (23 cm) and total-body (194 cm) systems. Eur J Nucl Med Mol Imaging 2021;48:3755-9. [PMID: 34424375 DOI: 10.1007/s00259-021-05505-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
93 Imura R, Ida H, Sasaki I, Ishioka NS, Watanabe S. Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of 89Zr Immune-PET Tracers. Molecules 2021;26:4977. [PMID: 34443566 DOI: 10.3390/molecules26164977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Chakravarty R, Chakraborty S. Production of a broad palette of positron emitting radioisotopes using a low-energy cyclotron: Towards a new success story in cancer imaging? Appl Radiat Isot 2021;176:109860. [PMID: 34284216 DOI: 10.1016/j.apradiso.2021.109860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
95 Klasen B, Lemcke D, Mindt TL, Gasser G, Rösch F. Development and in vitro evaluation of new bifunctional 89Zr-chelators based on the 6-amino-1,4-diazepane scaffold for immuno-PET applications. Nucl Med Biol 2021;102-103:12-23. [PMID: 34242949 DOI: 10.1016/j.nucmedbio.2021.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Jin Y, Liu B, Younis MH, Huang G, Liu J, Cai W, Wei W. Next-Generation Molecular Imaging of Thyroid Cancer. Cancers (Basel) 2021;13:3188. [PMID: 34202358 DOI: 10.3390/cancers13133188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Rosilawati NE, Yusuf M, Kartamihardja AHS, Samsuddin S, Muchtaridi M. Molecular dynamics simulation of Fe-NO2 At-alpha mangostin as radiopharmaceutical model for detection of fatty acid synthase in cancer. J Adv Pharm Technol Res 2021;12:113-9. [PMID: 34159140 DOI: 10.4103/japtr.JAPTR_188_20] [Reference Citation Analysis]
98 Bolzati C, Spolaore B. Enzymatic Methods for the Site-Specific Radiolabeling of Targeting Proteins. Molecules 2021;26:3492. [PMID: 34201280 DOI: 10.3390/molecules26123492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
99 Gao Y, Chen L, Ge J, Cui J, Zeng J, Gao M. A Pretargeting Strategy Enabled by Bioorthogonal Reactions Towards Advanced Nuclear Medicines: Application and Perspective. Chem Res Chin Univ 2021;37:870-9. [DOI: 10.1007/s40242-021-1179-2] [Reference Citation Analysis]
100 Guillou A, Earley DF, Klingler S, Nisli E, Nüesch LJ, Fay R, Holland JP. The Influence of a Polyethylene Glycol Linker on the Metabolism and Pharmacokinetics of a 89Zr-Radiolabeled Antibody. Bioconjug Chem 2021;32:1263-75. [PMID: 34056896 DOI: 10.1021/acs.bioconjchem.1c00172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
101 Bellotti D, Remelli M. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules 2021;26:3255. [PMID: 34071479 DOI: 10.3390/molecules26113255] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
102 Ankrah AO, Sathekge MM, Dierckx RAJO, Glaudemans AWJM. Radionuclide Imaging of Fungal Infections and Correlation with the Host Defense Response. J Fungi (Basel) 2021;7:407. [PMID: 34067410 DOI: 10.3390/jof7060407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
103 Chomet M, van Dongen GAMS, Vugts DJ. State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjug Chem 2021;32:1315-30. [PMID: 33974403 DOI: 10.1021/acs.bioconjchem.1c00136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
104 Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, Huo Y, Ferreira CA, Barnhart TE, Engle JW, Wang R, Jiang D, Xu X, Cai W. CD38-Targeted Theranostics of Lymphoma with 89Zr/177Lu-Labeled Daratumumab. Adv Sci (Weinh) 2021;8:2001879. [PMID: 34026426 DOI: 10.1002/advs.202001879] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
105 Qaim SM, Hussain M, Spahn I, Neumaier B. Continuing Nuclear Data Research for Production of Accelerator-Based Novel Radionuclides for Medical Use: A Mini-Review. Front Phys 2021;9:639290. [DOI: 10.3389/fphy.2021.639290] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
106 Wang W, Jin Y, Liu X, Chen F, Zheng X, Liu T, Yang Y, Yu H. Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer. Adv Funct Materials 2021;31:2100386. [DOI: 10.1002/adfm.202100386] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
107 Lu W, Cong Y, Yang D, Chen D, Yang G, Wang Y, Van Dort ME, Ross BD, Mazar AP, Chu BB, Hong H. Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography. Mol Pharm 2021;18:1690-8. [PMID: 33734721 DOI: 10.1021/acs.molpharmaceut.0c01139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Ferrari C, Maggialetti N, Masi T, Nappi AG, Santo G, Niccoli Asabella A, Rubini G. Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview. J Pers Med 2021;11:217. [PMID: 33803667 DOI: 10.3390/jpm11030217] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
109 Moazzam P, Myekhlai M, Alinezhad A, Alshawawreh FA, Bakthavathsalam P, Gonçales VR, Tilley RD, Gooding JJ. Ultrasensitive detection of programmed death-ligand 1 (PD-L1) in whole blood using dispersible electrodes. Chem Commun (Camb) 2021;57:2559-62. [PMID: 33586712 DOI: 10.1039/d0cc08068c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
110 González-Gómez R, Pazo-Cid RA, Sarría L, Morcillo MÁ, Schuhmacher AJ. Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography. J Clin Med 2021;10:1151. [PMID: 33801810 DOI: 10.3390/jcm10061151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
111 Iking J, Staniszewska M, Kessler L, Klose JM, Lückerath K, Fendler WP, Herrmann K, Rischpler C. Imaging Inflammation with Positron Emission Tomography. Biomedicines 2021;9:212. [PMID: 33669804 DOI: 10.3390/biomedicines9020212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
112 Gao A, Pan X, Yang X, Lin Z. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors. Invest New Drugs 2021;39:1132-8. [PMID: 33594603 DOI: 10.1007/s10637-021-01082-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
113 Zhao H, Wang C, Yang Y, Sun Y, Wei W, Wang C, Wan L, Zhu C, Li L, Huang G, Liu J. ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents. J Nanobiotechnology 2021;19:42. [PMID: 33563286 DOI: 10.1186/s12951-021-00785-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
114 Wang C, Chen Y, Hou YN, Liu Q, Zhang D, Zhao H, Zhang Y, An S, Li L, Hou J, Huang G, Liu J, Zhao YJ, Wei W. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging 2021;48:2749-60. [PMID: 33543326 DOI: 10.1007/s00259-021-05218-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
115 Lan X, Fan K, Li K, Cai W. Dynamic PET imaging with ultra-low-activity of 18F-FDG: unleashing the potential of total-body PET. Eur J Nucl Med Mol Imaging 2021. [PMID: 33515054 DOI: 10.1007/s00259-021-05214-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
116 Pietrobon V, Cesano A, Marincola F, Kather JN. Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors. Front Immunol 2020;11:604967. [PMID: 33584676 DOI: 10.3389/fimmu.2020.604967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
117 Kelly MP, Makonnen S, Hickey C, Arnold TC, Giurleo JT, Tavaré R, Danton M, Granados C, Chatterjee I, Dudgeon D, Retter MW, Ma D, Olson WC, Thurston G, Kirshner JR. Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues. J Immunother Cancer 2021;9:e002025. [PMID: 33483343 DOI: 10.1136/jitc-2020-002025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
118 Poulie CBM, Jørgensen JT, Shalgunov V, Kougioumtzoglou G, Jeppesen TE, Kjaer A, Herth MM. Evaluation of [64Cu]Cu-NOTA-PEG7-H-Tz for Pretargeted Imaging in LS174T Xenografts-Comparison to [111In]In-DOTA-PEG11-BisPy-Tz. Molecules 2021;26:544. [PMID: 33494416 DOI: 10.3390/molecules26030544] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
119 Kumar K, Ghosh A. Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124. Molecules 2021;26:E414. [PMID: 33466827 DOI: 10.3390/molecules26020414] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
120 Pietrobon V, Marincola FM. Hypoxia and the phenomenon of immune exclusion. J Transl Med 2021;19:9. [PMID: 33407613 DOI: 10.1186/s12967-020-02667-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 28.0] [Reference Citation Analysis]
121 Ross TL, Ametamey SM. PET Chemistry: An Introduction. Basic Sciences of Nuclear Medicine 2021. [DOI: 10.1007/978-3-030-65245-6_7] [Reference Citation Analysis]
122 Lee W, Bobba KN, Kim JY, Park H, Bhise A, Kim W, Lee K, Rajkumar S, Nam B, Lee KC, Lee SH, Ko S, Lee HJ, Jung ST, Yoo J. A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high-contrast immuno-PET images. J Mater Chem B 2021;9:2993-7. [DOI: 10.1039/d0tb02911d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
123 Kurebayashi Y, Choyke PL, Sato N. Imaging of cell-based therapy using 89Zr-oxine ex vivo cell labeling for positron emission tomography. Nanotheranostics 2021;5:27-35. [PMID: 33391973 DOI: 10.7150/ntno.51391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
124 Munch M, Rotstein BH, Ulrich G. Fluorine-18-Labeled Fluorescent Dyes for Dual-Mode Molecular Imaging. Molecules 2020;25:E6042. [PMID: 33371284 DOI: 10.3390/molecules25246042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
125 Bouleau A, Lebon V, Truillet C. PET imaging of immune checkpoint proteins in oncology. Pharmacol Ther 2021;222:107786. [PMID: 33307142 DOI: 10.1016/j.pharmthera.2020.107786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
126 Filippi L, Nervi C, Proietti I, Pirisino R, Potenza C, Martelli O, Equitani F, Bagni O. Molecular imaging in immuno-oncology: current status and translational perspectives. Expert Rev Mol Diagn 2020;20:1199-211. [PMID: 33215963 DOI: 10.1080/14737159.2020.1854090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
127 van Dongen GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, van Kuijk C, Boellaard R, Huisman MC, Vugts DJ. The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. J Nucl Med 2021;62:438-45. [PMID: 33277395 DOI: 10.2967/jnumed.119.239558] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
128 Gunzer M, Thornton CR, Beziere N. Advances in the In Vivo Molecular Imaging of Invasive Aspergillosis. J Fungi (Basel) 2020;6:E338. [PMID: 33291706 DOI: 10.3390/jof6040338] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
129 Gettemans J, De Dobbelaer B. Transforming nanobodies into high-precision tools for protein function analysis. Am J Physiol Cell Physiol 2021;320:C195-215. [PMID: 33264078 DOI: 10.1152/ajpcell.00435.2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
130 Zaharchuk G, Davidzon G. Artificial Intelligence for Optimization and Interpretation of PET/CT and PET/MR Images. Semin Nucl Med 2021;51:134-42. [PMID: 33509370 DOI: 10.1053/j.semnuclmed.2020.10.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
131 Kukkar D, Kukkar P, Kumar V, Hong J, Kim KH, Deep A. Recent advances in nanoscale materials for antibody-based cancer theranostics. Biosens Bioelectron 2020;173:112787. [PMID: 33190049 DOI: 10.1016/j.bios.2020.112787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
132 Ma D, Zhu Q. MOF-based atomically dispersed metal catalysts: Recent progress towards novel atomic configurations and electrocatalytic applications. Coordination Chemistry Reviews 2020;422:213483. [DOI: 10.1016/j.ccr.2020.213483] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 35.5] [Reference Citation Analysis]
133 Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules 2020;25:E4764. [PMID: 33081383 DOI: 10.3390/molecules25204764] [Cited by in Crossref: 70] [Cited by in F6Publishing: 81] [Article Influence: 35.0] [Reference Citation Analysis]
134 Guo X, Li Y, Zhang M, Cao K, Tian Y, Qi Y, Li S, Li K, Yu X, Ma L. Colyliform Crystalline 2D Covalent Organic Frameworks (COFs) with Quasi‐3D Topologies for Rapid I 2 Adsorption. Angew Chem Int Ed 2020;59:22697-705. [DOI: 10.1002/anie.202010829] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 30.5] [Reference Citation Analysis]
135 Guo X, Li Y, Zhang M, Cao K, Tian Y, Qi Y, Li S, Li K, Yu X, Ma L. Colyliform Crystalline 2D Covalent Organic Frameworks (COFs) with Quasi‐3D Topologies for Rapid I 2 Adsorption. Angew Chem 2020;132:22886-94. [DOI: 10.1002/ange.202010829] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
136 Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DB, Punzalan B, Pillarsetty NVK, Xu H, Guo HF, Monette S, Michel AO, Piersigilli A, Scheinberg DA, Ouerfelli O, Cheung NV, Larson SM. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics 2020;10:11359-75. [PMID: 33052220 DOI: 10.7150/thno.48810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
137 Chomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, Poot AJ, Windhorst AD, Gill H, Marik J, Williams S, Cowell J, Gasser G, Mindt TL, van Dongen GAMS, Vugts DJ. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging 2021;48:694-707. [PMID: 32889615 DOI: 10.1007/s00259-020-05002-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
138 Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, Xu X, Cai W. Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab')2 Fragments of Obinutuzumab in Lymphoma. J Nucl Med 2021;62:372-8. [PMID: 32826320 DOI: 10.2967/jnumed.120.246595] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
139 Coenen HH, Ermert J. Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18. Nucl Med Biol 2021;92:241-69. [PMID: 32900582 DOI: 10.1016/j.nucmedbio.2020.07.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
140 Wei W, Liu Q, Jiang D, Zhao H, Kutyreff CJ, Engle JW, Liu J, Cai W. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. Adv Sci (Weinh) 2020;7:1903595. [PMID: 32670751 DOI: 10.1002/advs.201903595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
141 Otaru S, Niemikoski H, Sarparanta M, Airaksinen AJ. Metabolism of a Bioorthogonal PET Tracer Candidate [19F/18F]SiFA-Tetrazine in Mouse Liver Microsomes: Biotransformation Pathways and Defluorination Investigated by UHPLC-HRMS. Mol Pharm 2020;17:3106-15. [PMID: 32539414 DOI: 10.1021/acs.molpharmaceut.0c00523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Bailly C, Chalopin B, Gouard S, Carlier T, Saëc PR, Marionneau-Lambot S, Moreau P, Touzeau C, Kraeber-Bodere F, Bodet-Milin C, Chérel M. ImmunoPET in Multiple Myeloma-What? So What? Now What? Cancers (Basel) 2020;12:E1467. [PMID: 32512883 DOI: 10.3390/cancers12061467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]